E
Emmaus Life Sciences, Inc.
EMMA
$0.0155
-$0.0015-8.82%
E
Sell
1/6/2025Downgrade
Emmaus Life Sciences, Inc. (EMMA) was downgraded to E+ from D- on 1/6/2025 due to a significant decline in the growth index, valuation index and solvency index.
Emmaus Life Sciences, Inc. (EMMA) was downgraded to E+ from D- on 1/6/2025 due to a significant decline in the growth index, valuation index and solvency index.
D
Sell
9/11/2024Upgraded
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D- from E+ on 9/11/2024 due to a significant increase in the growth index, valuation index and volatility index. EBIT increased 5,545.83% from $24 to $1.36M, earnings per share increased from $0.0005 to $0.0178, and operating cash flow increased 1,686.21% from $58 to $1.04M.
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D- from E+ on 9/11/2024 due to a significant increase in the growth index, valuation index and volatility index. EBIT increased 5,545.83% from $24 to $1.36M, earnings per share increased from $0.0005 to $0.0178, and operating cash flow increased 1,686.21% from $58 to $1.04M.
E
Sell
5/12/2023Downgrade
Emmaus Life Sciences, Inc. (EMMA) was downgraded to E+ from D- on 5/12/2023 due to a decline in the volatility index and total return index.
Emmaus Life Sciences, Inc. (EMMA) was downgraded to E+ from D- on 5/12/2023 due to a decline in the volatility index and total return index.
D
Sell
4/25/2023Upgraded
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D- from E+ on 4/25/2023 due to an increase in the volatility index and total return index.
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D- from E+ on 4/25/2023 due to an increase in the volatility index and total return index.
E
Sell
4/6/2023Downgrade
Emmaus Life Sciences, Inc. (EMMA) was downgraded to E+ from D- on 4/6/2023 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 0.06 to 0.04.
Emmaus Life Sciences, Inc. (EMMA) was downgraded to E+ from D- on 4/6/2023 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 0.06 to 0.04.
D
Sell
4/3/2023Upgraded
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D- from E+ on 4/3/2023 due to an increase in the volatility index.
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D- from E+ on 4/3/2023 due to an increase in the volatility index.
E
Sell
3/16/2023Downgrade
Emmaus Life Sciences, Inc. (EMMA) was downgraded to E+ from D- on 03/16/2023.
Emmaus Life Sciences, Inc. (EMMA) was downgraded to E+ from D- on 03/16/2023.
D
Sell
1/25/2023Upgraded
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D- from E+ on 1/25/2023 due to an increase in the total return index and volatility index.
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D- from E+ on 1/25/2023 due to an increase in the total return index and volatility index.
E
Sell
1/10/2023Downgrade
Emmaus Life Sciences, Inc. (EMMA) was downgraded to E+ from D- on 1/10/2023 due to a decline in the volatility index.
Emmaus Life Sciences, Inc. (EMMA) was downgraded to E+ from D- on 1/10/2023 due to a decline in the volatility index.
D
Sell
12/12/2022Upgraded
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D- from E+ on 12/12/2022 due to an increase in the volatility index and total return index.
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D- from E+ on 12/12/2022 due to an increase in the volatility index and total return index.
E
Sell
11/25/2022Downgrade
Emmaus Life Sciences, Inc. (EMMA) was downgraded to E+ from D- on 11/25/2022 due to a decline in the growth index and solvency index.
Emmaus Life Sciences, Inc. (EMMA) was downgraded to E+ from D- on 11/25/2022 due to a decline in the growth index and solvency index.
D
Sell
8/17/2022Downgrade
Emmaus Life Sciences, Inc. (EMMA) was downgraded to D- from D on 8/17/2022 due to a noticeable decline in the growth index, volatility index and solvency index. Earnings per share declined from -$0.0313 to -$0.1803, debt to equity increased from -0.96 to -0.71, and the quick ratio declined from 0.05 to 0.05.
Emmaus Life Sciences, Inc. (EMMA) was downgraded to D- from D on 8/17/2022 due to a noticeable decline in the growth index, volatility index and solvency index. Earnings per share declined from -$0.0313 to -$0.1803, debt to equity increased from -0.96 to -0.71, and the quick ratio declined from 0.05 to 0.05.
D
Sell
8/15/2022Upgraded
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D from D- on 8/15/2022 due to an increase in the volatility index and valuation index.
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D from D- on 8/15/2022 due to an increase in the volatility index and valuation index.
D
Sell
7/27/2022Downgrade
Emmaus Life Sciences, Inc. (EMMA) was downgraded to D- from D on 7/27/2022 due to a decline in the volatility index and total return index.
Emmaus Life Sciences, Inc. (EMMA) was downgraded to D- from D on 7/27/2022 due to a decline in the volatility index and total return index.
D
Sell
7/11/2022Upgraded
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D from D- on 7/11/2022 due to an increase in the volatility index.
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D from D- on 7/11/2022 due to an increase in the volatility index.
D
Sell
6/21/2022Downgrade
Emmaus Life Sciences, Inc. (EMMA) was downgraded to D- from D on 6/21/2022 due to a decline in the total return index and volatility index.
Emmaus Life Sciences, Inc. (EMMA) was downgraded to D- from D on 6/21/2022 due to a decline in the total return index and volatility index.
D
Sell
5/20/2022Upgraded
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D from D- on 5/20/2022 due to a large increase in the growth index. Earnings per share increased from -$0.1392 to -$0.0313, EBIT increased 38.21% from -$4.97M to -$3.07M, and total revenue increased 7.09% from $3.02M to $3.23M.
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D from D- on 5/20/2022 due to a large increase in the growth index. Earnings per share increased from -$0.1392 to -$0.0313, EBIT increased 38.21% from -$4.97M to -$3.07M, and total revenue increased 7.09% from $3.02M to $3.23M.
D
Sell
5/5/2022Upgraded
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D- from E+ on 5/5/2022 due to an increase in the growth index.
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D- from E+ on 5/5/2022 due to an increase in the growth index.
E
Sell
4/20/2022Downgrade
Emmaus Life Sciences, Inc. (EMMA) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index.
Emmaus Life Sciences, Inc. (EMMA) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index.
D
Sell
4/18/2022Downgrade
Emmaus Life Sciences, Inc. (EMMA) was downgraded to D- from D on 4/18/2022 due to a major decline in the growth index, total return index and volatility index. EBIT declined 15,916.13% from -$31 to -$4.97M, earnings per share declined from -$0.0639 to -$0.1392, and total revenue declined 47.62% from $5.77M to $3.02M.
Emmaus Life Sciences, Inc. (EMMA) was downgraded to D- from D on 4/18/2022 due to a major decline in the growth index, total return index and volatility index. EBIT declined 15,916.13% from -$31 to -$4.97M, earnings per share declined from -$0.0639 to -$0.1392, and total revenue declined 47.62% from $5.77M to $3.02M.
D
Sell
11/9/2021Upgraded
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D from E+ on 11/09/2021.
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Emmaus Life Sciences, Inc. (EMMA) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index, solvency index and valuation index.
Emmaus Life Sciences, Inc. (EMMA) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index, solvency index and valuation index.
D
Sell
9/2/2021Downgrade
Emmaus Life Sciences, Inc. (EMMA) was downgraded to D from C- on 9/2/2021 due to a significant decline in the efficiency index, growth index and valuation index. EBIT declined 20,287.5% from $8 to -$1.62M, net income declined 250.8% from $5.59M to -$8.42M, and earnings per share declined from $0.114 to -$0.1716.
Emmaus Life Sciences, Inc. (EMMA) was downgraded to D from C- on 9/2/2021 due to a significant decline in the efficiency index, growth index and valuation index. EBIT declined 20,287.5% from $8 to -$1.62M, net income declined 250.8% from $5.59M to -$8.42M, and earnings per share declined from $0.114 to -$0.1716.
C
Hold
8/30/2021Upgraded
Emmaus Life Sciences, Inc. (EMMA) was upgraded to C- from D on 8/30/2021 due to a significant increase in the efficiency index, growth index and valuation index. Net income increased 158.96% from -$9.47M to $5.59M, earnings per share increased from -$0.1934 to $0.114, and total capital increased 103.15% from $6.94M to $14.11M.
Emmaus Life Sciences, Inc. (EMMA) was upgraded to C- from D on 8/30/2021 due to a significant increase in the efficiency index, growth index and valuation index. Net income increased 158.96% from -$9.47M to $5.59M, earnings per share increased from -$0.1934 to $0.114, and total capital increased 103.15% from $6.94M to $14.11M.
D
Sell
8/27/2021Upgraded
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D from D- on 8/27/2021 due to a noticeable increase in the total return index and volatility index.
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D from D- on 8/27/2021 due to a noticeable increase in the total return index and volatility index.
D
Sell
4/1/2020Upgraded
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D- from E on 04/01/2020.
Emmaus Life Sciences, Inc. (EMMA) was upgraded to D- from E on 04/01/2020.
E
Sell
1/2/2020Upgraded
Emmaus Life Sciences, Inc. (EMMA) was upgraded to E from E- on 1/2/2020 due to a noticeable increase in the efficiency index and total return index.
Emmaus Life Sciences, Inc. (EMMA) was upgraded to E from E- on 1/2/2020 due to a noticeable increase in the efficiency index and total return index.
E
Sell
10/10/2019None
Emmaus Life Sciences, Inc. (EMMA) was downgraded to E- from U on 10/10/2019.
Emmaus Life Sciences, Inc. (EMMA) was downgraded to E- from U on 10/10/2019.
OTC PK
04/08/2025 10:58AM Eastern
Quotes delayed
